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Abstract
Background: Shifts in clinical trial application rates over time indicate if the attractiveness of a country or region
for the conduct of clinical trials is growing or decreasing. The purpose of this observational study was to track
changes in drug trial application patterns across several EU countries in order to analyze the medium-term impact
of the EU Clinical Trials Directive 2001/20/EC on the conduct of drug trials.
Methods: Rates of Clinical Trial Applications (CTA) for studies with medicinal products in those six countries in the
EU, which authorize on average more than 500 trials per year, were analyzed. Publicly available figures on the
number of annually submitted CTA, the distribution of trials per phase and the type of sponsorship were tracked;
missing data were provided by national drug agencies.
Results: Since 2001, the number of CTA in Italy and Spain increased significantly (5.0 and 2.5% average annual
growth). For Italy, the gain was driven by a strong increase of applications from academic trial sponsors; Spain’s
growth was due to a rise in trials run by commercial sponsors. The Netherlands, Germany, France and the UK saw
a decline (1.9, 2.3, 3.0 and 5.3% average annual diminution; significant (P < 0.05) except for Germany) in clinical
drug trials. The decrease in the UK was caused by a sharp fall in academic trial activities. Across the six analyzed
countries, no EU-wide trial-phase-specific patterns or trends were observed.
Conclusions: The EU Clinical Trials Directive 2001/20/EC did not achieve the harmonization of clinical trial
requirements across Europe. Rather, it resulted in the leveling of clinical trial activities caused by a continuing
decrease in CTA rates in the Netherlands, Germany, France and the UK. Southern European countries, Italy and
Spain, benefited to some extent from policy changes introduced by the Directive. In Italy’s case, national funding
measures helped to considerably promote the conduct of non-commercial trials. On the other hand, the EU
Directive-driven transition from liberal policy environments, based on non-explicit trial approval through
notifications, towards red-taped processes of trial authorization, contributed to the decreases in trial numbers in
Germany and the UK. In the latter case, national research governance concerns had a share in the country’s
marked decline. However, different EU member states successfully developed best practices, which a new
European legislation should take into consideration to resume Europe’s attractiveness and international
competitiveness for the conduct of clinical trials.
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A strong clinical research sector and efficient trial infra-
structures are deemed to be key requisites for a coun-
try’so rr e g i o n ’s capability to successfully contribute to
the development of innovative health care products and
to the evidence-based evaluation of the value and effec-
tiveness of innovative as well as established products.
The availability of sufficiently large pools of patients for
inclusion in clinical trials, the rapidity of study set-up
and recruitment of trial participants, the existence of a
legal framework ensuring and promoting the GCP-like
conduct of trials, and the general intention to keep the
costs of any research endeavor as low as possible, con-
stitute other commonly acknowledged elements for a
country’s or region’s competitive capacity in a globalized
clinical research landscape.
During the last decade, the true globalization of clini-
cal research impacted tremendously on the perception
of how clinical research would evolve further, raising
some concerns in the United States about the future
relevance of US-centered clinical drug research and the
ethical and scientific implications of research globaliza-
tion [1,2]. In Europe, the discussions on the continent’s
future role in clinical research focused most on the
impact of the European Union Clinical Trials Directive
(EUCTD) [3]. Intended to harmonize and simplify clini-
cal trial requirements across the European Union (EU)
and to sustain innovation and competitiveness, the
Directive was widely bemoaned to raise legal obstacles,
bureaucracy, work load and costs and to undermine
Europe’s position in clinical research [4]. Adopted in
2001, the Directive asked for implementation of its
requirements until 1 May 2004 - the same day when 10
new member states from central, eastern and southern
Europe entered the EU. Due to the complexity of the
legal transposition process, many member states did not
meet this deadline. Some states, among them France
and the Netherlands, implemented the act with a two-
year delay.
Especially, academic researchers continued to criti-
cize the EUCTD - reference 4 provides a nice snapshot
of the length and amplitude of the harsh discussions -
and pushed, in line with pharmaceutical trade associa-
tions, the EU Commission to act. The Commission,
the responsible policy maker in the field of clinical
research, held a stakeholder conference investigating
the operation of the EUCTD [5] in October 2007, in
cooperation with the European Medicines Agency
(EMA). After the conference and two comprehensive
follow-up evaluations of the situation [6,7], the Eur-
opean Commission finally led a public consultation on
the functioning of the Directive [8] and engaged, as an
outcome of the consultation process [9], in a process
to revise the legal framework for clinical drug research
in the EU [10,11].
Despite several initiatives to analyze the situation of
clinical drug research in the EU and to define priorities
for future action, apart from single-country- or single-
trial-based situation-analyses, only few overall data sets
were available allowing to quantify the true impact of
the EUCTD. One project (ICREL) provided an EU-wide
situation analysis with focus on changes observed
between 2003 and 2007 [6]. Given the aforementioned,
the present study was initiated in 2006 to benchmark
patterns and trends in the clinical research activities in
Europe in the form of a prior-posterior analysis. Assum-
ing that the detailed outcomes of the policy changes
were to measure most adequately in those western Eur-
opean countries that had played for decades a leading
role in clinical drug development data from these coun-
tries were retro- and prospectively collected. It was
assumed that data from these core countries might
serve as a surrogate for Europe’s clinical research activ-
ity and competitiveness. Taking into account the lengthy
implementation process of the EUCTD in several coun-
tries, a follow-up, including data until 2009, was deemed
necessary to determine reliable pre- and post-implemen-
tation figures for comparison.
Methods
Clinical trial applications (CTA) for studies with medic-
inal products in those six countries in the European
Union (EU) (France, Germany, Italy, the Netherlands,
Spain and the United Kingdom), which authorize on
average more than 500 drug trials per year, were ana-
lyzed. The relatively large national drug agencies in
these countries provide sufficiently detailed metrics to
analyze overall patterns as well as specific variables over
the whole observation period. The analysis covers the
period from 2001, the year of publication of the
EUCTD, until 2009. Publicly available figures from
national drug agencies (performance metrics, annual
reports and statistics) on the number of annually sub-
mitted CTA were tabulated; the distribution of trials per
phase and sponsor-type was tracked as well. On request,
national competent authorities (NCA) had added miss-
ing information, mainly with regard to the distribution
of sponsorship (commercial sponsors (CS) versus non-
commercial sponsors (NCS)) - a differentiation originat-
ing from the EUCTD and defined in the EU Commis-
sion’s initial accompanying guidance [12] as follows: “A
commercial sponsor is a person or organization that
takes responsibility for a trial which at the time of the
application is part of a development programme for a
marketing authorisation of a medicinal product”. Linear
regression analysis was used to determine trends over
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(AAGR), a measure used to determine trends in the glo-
balization of clinical trials [2,13], were calculated on the
basis of the linear regression equation. It was assumed
that the numerous factors impacting on a sponsor’s
decision to set-up a clinical research project and to sub-
mit a CTA for a given trial in one or several countries
were leading to a quasi-linear course of applications
over time. In this model, changes in a country’s attrac-
tiveness for clinical research are displayed by the
gradient.
In order to better take into account the individual
country-specificities of the legal implementation process
regarding the factors ‘sponsorship’ and ‘trial phase’, per-
country arithmetic means of pre- and post-implementa-
tion CTA figures were determined on the basis of the
number of applications in three consecutive years prior
to and after the time point (or, in the case of France,
time period), when the legal requirements changed. The
significance of the impact was determined by the com-
parison of the means of trial application rates (unpaired
t-test, assuming that variability of each sample is due to
the sum of numerous independent factors). P-values ≤
0.05 were considered to indicate significance. P-values ≤
0.001 were considered to be highly significant. Data
were analyzed with MedCalc Statistical Software Version
11.1.1.0 (MedCalc, Inc., Mariakerke, Belgium).
Results
Overall patterns
O v e rap e r i o do fn i n ey e a r s ,ad e c r e a s ei nC T Ar a t e s
was observed in the Netherlands, Germany, France and
the United Kingdom, as determined by the AAGR (Fig-
ure 1). In Spain and Italy, the number of CTA was stea-
dily growing. For Germany the delayed implementation
of the EUCTD in August 2004 represented a major
switch from a trial notification to a trial authorization
system. A steep increase of old-style notifications was
hence observed in the spring and early summer 2004.
The resulting peak in applications depicts that many
sponsors anticipated increased workload and costs intro-
duced by the new legislation - a country-specific effect
impacting on the reposted determination coefficient and
statistical significance, too. Exploratory drug trials of
minimal or non-interventional character were exempted
from notification prior to August 2004; for this reason,
the implementation of the EUCTD induced some bias
in Germany’s annual accounting for trial applications. It
is estimated that trials with such ‘minor interventional
character’, mostly conducted by practitioners and aca-
demic study groups, might have contributed to a 10 to
20% higher rate of total applications in the period 2001
to 2004. In the UK, trials with healthy volunteers, which
include the vast majority of all phase I trials, were
exempted from prior approval or notification prior to
May 2004 [14]. Therefore, reported figures for the UK
do not account for phase I trials.
In Figure 2, the population-size-adjusted clinical trial
activity across the six EU member states over time is
shown in terms of arithmetic means (numbers of initial
CTA per country) for three consecutive years. The fig-
ure illustrates well that the ultimate outcome of the
EUCTD results in the leveling of clinical trials activities
across the six analyzed EU member states. Remarkable
is the fact that the clinical trial density in the Nether-
lands is still much higher than in the other countries.
The finding might be explained by the organization of
the Dutch health care sector with a dominant role of
hospitals for in-patient as well as for ambulatory care in
line with the high population density and a traditionally
open and positive attitude of the population and regulat-
ing authorities towards clinical drug research. This
structural and behavioral vantage contributes also, in
terms of the publication activity, to an internationally
remarkable position of the Netherlands in clinical
research: only the Scandinavian countries show higher
per-capita publication rates [15].
Impact of sponsorship
In Table 1, the findings regarding the impact of the fac-
tor ‘sponsorship’ are outlined. Only Italy showed a
highly significant increase in non-commercial trial activ-
ities. In other countries, non-commercial trials either
contributed less to the growth of trial activities than
trials run by commercial sponsors (Spain), or were driv-
ing factors behind the observed general decline of appli-
cations (France, UK). Regarding both southern
European countries, the comparison of means (Table 1,
bottom) indicates that the growth in CTA in Italy was
driven by non-commercial sponsors, whereas the
observed growth in Spain was due to an increased activ-
ity of commercial sponsors. For the UK, the highly sig-
nificant drop in trial activities just after the policy
change confirms that the country’s overall loss in trial
applications over the last decade was predominantly
caused by a decline of trial activities of non-commercial
sponsors.
Trial phase specific patterns
All in all, no trial phase specific trends, interpretable as
EU-wide exodus or influx of trials of a given phase or as
intra-European shifts, were found (Table 1). In Germany
and France, a significant cutback in phase I trial activ-
ities was observed. It is assumed that the cutback is
even more accentuated in the UK, but due to the fact
that the majority of phase I trials - those with ‘healthy’
volunteers - were exempted from notification and any
regulatory supervision prior to May 2004, no data
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the fact that in Italy and Spain the proportion of phase I
trials, compared to other trial phases, is still quite low -
an observation which might be explained historically: by
socio-cultural attitudes towards trials with no, or a very
uncertain, direct therapeutic benefit for the participant
on the one hand, and most notably by the absence of a
relevant infrastructure of Phase I units on the other
hand.
Numbers of phase II trials were augmented signifi-
cantly in Spain and Italy; the latter being the only coun-
try reporting a slight increase in phase III trials as well.
In contrast to this, the number of phase III trials in the
Netherlands and Germany fell significantly. For the UK,
detailed trial phase figures prior to 2004 were not
tracked by the authorities; hence a prior-posterior analy-
sis of means is not feasible.
Regarding phase IV trials, the observed highly signifi-
cant decrease in France is noteworthy; for the Nether-
lands, as well, a decrease was noted. Due to the rising
importance of phase IV trials in terms of post-approval
market surveillance of newly approved as well as estab-
lished medicines, rising rather than declining figures
were expected, as documented indeed for Spain, Ger-
many and, particularly, Italy.
As outlined before, ‘Therapy Optimization Studies’ of
minor-interventional or non-interventional character
were to some extent exempted prior to August 2004
from regulatory supervision, notably in Germany. The
country’s observed strong growth in phase IV trials
since 2004 might be explained partly by this change in
the regulatory policy. The concept and definition of
what constitutes an interventional phase IV trial is still
not harmonized across the EU. This might contribute to
some bias in the accounting of phase IV CTA.
Discussion
This paper provides a medium-term analysis of changes
in clinical trial applications over time in six EU member
states. An observation period of nine years (2001 to
2009) was deemed indispensable, to adequately track
and compare application rates prior and posterior to the
implementation of the EUCTD across Europe which
took place between 2004 and 2006. As a snapshot in
time, the results of the linear regression analysis do
neither allow for extrapolation out of the observation
period, nor any prevision about changes in CTA rates in
other European countries. Similarly the reported prior-
posterior means only allow for detection of trends and
shifts within each country. Due to multiple applications
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Country  AAGR (R²)  p-value
IT +5.0%  (0.74)  p=0.003
ES +2.5% (0.70)  p=0.005
NL  -1.9% (0.50)   p=0.034
FR -3.0% (0.68)   p=0.006
UK -5.3% (0.61)   p=0.013
DE -2.3% (0.22)   p=0.2    
Figure 1 Annual Clinical Trial Applications (CTA) and Average Annual Growth Rates (AAGR) for the period 2001 to 2009.F i g u r e sf o r
Germany comprise merged data for both national competent authorities (BfArM and the Paul-Ehrlich-Institute). Figures for the UK do not
comprise phase I trials (often referred to in the UK as ‘trials with healthy volunteers’).
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inter-country comparison of proportions or a summa-
tion of either means or trial approval numbers of all
countries would be strongly biased and, therefore, mis-
leading, especially for trial phases II, III and IV. Empha-
sis must be placed on the fact that in such prior-
posterior studies one can never be certain to what
degree unconsidered confounders are present - any
interpretation of the presented data hence carries risks
of making wrong interferences [16].
Regarding the main objective of this study, the assess-
ment of the medium-term impact of the EUCTD on
CTA rates in six relevant EU countries, several conclu-
sions can be inferred from the above-presented results.
First, over the last decade clinical drug research was not
struggling in all countries covered by this analysis; the
often bemoaned general negative effect [17,18] of the
EUCTD on clinical drug research across Europe can not
be generalized. The results indicate that the relative
attractiveness of Italy and Spain for the conduct of trials
has grown -commercial trial sponsors especially pay
attention to factors such as trial set-up and approval
times, improved GCP adherence or streamlined report-
ing requirements. Further analyses would be of interest
to determine if other southern, but also eastern, EU
countries also benefited from the implementation of the
EUCTD.
Secondly, the results confirm that non-commercial
trial sponsors reacted more sensitively to changes in the
regulatory policy. The decline of the UK as well as the
rise of Italy - the two most significant trends detected
by this study - were both driven by striking shifts in the
activity of academic trial sponsors. For non-commercial
sponsors, costs and work-load related to the set-up and
conduct of a trial were repeatedly reported to be deter-
mined for their capability to run clinical trials [19,20].
In this regard, the sponsor-specific variances in the
CTA patterns are worth further discussion. Since 2003,
Italy has applied a unique set of accompanying measures
to foster clinical research [21]. In line with the imple-
mentation of the EUCTD, the specific needs of aca-
demic sponsors were encountered by an explicit
[n per million inhabitants]
Country
0
10
20
30
40
2001-03 2004-06 2007-09
IT
ES
NL
DE
FR
UK
[Time period]
Figure 2 Population-size-adjusted clinical trial activity across six EU member states. The ultimate outcome of the EUCTD results in the
leveling of clinical trials activities across the six analyzed EU member states. As in the previous figure, UK data do not include phase I trials.
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the national legislation, extra provisions for the cost
takeover of Investigational Medicinal Products (IMP), as
well as waivers of fees for the consultation of ethics
committees and the Italian national competent author-
ity. Particular alleviations for ‘therapeutic strategy trials’,
everywhere a domain of investigator-driven research,
have been laid down in Italy’s legal decree on non-profit
studies [22], an act unique in its kind in Europe [23]. In
addition, a five percent levy on all promotional budgets
of pharmaceutical companies was decreed to generate
meaningful funding for independent drug research [24].
On the other hand, in 2009 another decree laid down
minimum requirements for insurance policies which
safeguard participants in clinical trials of medicinal pro-
ducts [25]. Asked to extend their existing insurance cov-
erage to explicitly imply clinical trial activities or to set-
up additional indemnity-covering insurances, many Ita-
lian institutions began to limit the number of trials
initiated by their staff. As a consequence, in 2009, the
number of non-commercial trials in Italy slumped for
the first time after eight years of a consecutive rise.
This example shows that national policy-making is
still highly influential on the conduct of trials. A second
example concerns the UK, where the Department of
Health, concerned by the observed strong decline of
trial activities since 2003, began in 2006 to establish
model clinical trial agreements. The department argued
that such “nationally approved standard agreements help
speed up the contracting process for clinical trials car-
ried out in the NHS”. The agreements are part of a sys-
tem of reforms to streamline the process of conducting
clinical trials in the National Health Service (NHS) [26].
It is assumed that the initiative, which was gratefully
acknowledged by independent research organizations as
well as by commercial sponsors, contributed to a certain
extent to a temporary stabilization of CTA rates, as
observed since 2006 (see Figure 1).
However, the situation in the UK remains a source of
concern for clinical researchers as well as for national
policy-makers. Findings from British investigators depict
that, apart from the additional administrative burden
introduced by the EUCTD in 2004, UK-specific artifacts
in the trial authorization and supervision process con-
tinued to render clinicians’ lives difficult [27]. The
changes within the research ethics committees system
produced a lot of insecurity, an over-interpretation of
requirements, as well as a huge increase in required
documentation. Indeed, local research facility scientific
advisory committees had been set-up inside many regio-
nal trusts of the NHS resulting in a new multiplicity of
ethics approvals. Different attitudes within the NHS
were also observed in terms of research governance, as
well as in indemnity and liability take-over, rendering
the conduct of UK-wide multi-center studies quite com-
plicated. These particularities caused the National Insti-
tute of Health Research (NIHR) in 2008 to establish a
“bureaucracy busting mission”, and the government to
Table 1 Sponsorship and trial-phase specific patterns: AAGR (A) and prior-posterior implementation means (B)
All trials CS trials NCS trials Ph I trials Ph II trials Ph III trials Ph IV trials
A AAGR (Period 2001 to 2009) (%)
IT +5.0* +1.3 +13.0** +32.8** +6.3* +1.5 +14.7**
ES +2.5* +3.1 +0.7 +2.5 +7.1* -1.1 +5.5
NL -1.9* -2.0* -1.9 +1.1 -3.8* -2.8* -5.7*
DE -2.3 –– -5.3* -1.6 -4.3* +6.4
FR -3.0* -2.8* -3.4* -4.5* -0.3 -0.7 -7.3**
UK -5.3* -0.4 -15.2* ––––
B Means (Prior-Posterior Comparison) (n CTA)
IT
1 587 ⇨ 744* 433 ⇨ 479 153 ⇨ 260* 9 ⇨ 21* 206 ⇨ 280* 311 ⇨ 344 47 ⇨ 87*
ES
1 576 ⇨ 626 446 ⇨ 556 130 ⇨ 104 90 ⇨ 92 142 ⇨ 175 278 ⇨ 272 67 ⇨ 101
NL
2 697 ⇨ 597* 405 ⇨ 351 292 ⇨ 246 139 ⇨ 126 161 ⇨ 132 203 ⇨ 177 73 ⇨ 67
DE
1 1,497 ⇨1,428* (1,300) ⇨ 1,170 (197) ⇨ 259 462 ⇨ 340* 340 ⇨ 321 437 ⇨ 368* 65 ⇨ 144*
FR
3 1,165 ⇨ 973* 885 ⇨ 727* 310 ⇨ 247* 288 ⇨ 221* 291 ⇨ 288 365 ⇨ 350 160 ⇨ 101*
UK
1,4 1,248 ⇨ 832** 656 ⇨ 576** 592 ⇨ 256** nd ⇨ (301) nd ⇨ 353 nd ⇨ 261 nd ⇨ 218
In the case of Germany, exact distribution patterns for sponsorship could not been established for the period prior May 2004, the reported mean (n = 197) refers
exclusively to studies initiated by universities or university hospitals. For the UK, trial phase specific distribution patterns prior to 2004 are unknown.
1: IT, ES, DE, UK: Means of three consecutive years prior to implementation (2001 to 2003) versus means for period posterior to implementation (2005 to 2007)
2: NL: Means of three consecutive years ‘prior’ (2003 to 2005) versus means for years ‘posterior’ to implementation (2007 to 2009)
3: FR: Means of three consecutive years ‘prior’ (2001 to 2003) versus years ‘posterior’ (2007 to 2009). Transition period for implementation of EUCTD in France:
2004 to 2006
4: UK: Means (All trials, CS trials, NCS trials) do not account for phase I trials (’trials with healthy volunteers’)
CS/NCS, Commercial/Non-commercial Sponsor; nd, no data; *, significant, defined as P ≤ 0.05; **, highly significant, defined as P ≤ 0.001
Hartmann Trials 2012, 13:53
http://www.trialsjournal.com/content/13/1/53
Page 6 of 10ask the Academy of Medical Sciences to thoroughly
review the current regulatory and governance environ-
ment around research. Recommendations from this
working group were published in early 2011 and may
pay off in the coming years [28].
Many of the specific findings discussed above, such as
the unprecedented decline of clinical research in the UK
between 2002 and 2006 or the rise of phase IV trials in
Germany, had been previously reported in the form of
single observations [29,30]. On the other hand, only a
few other publications analyzing medium- to long-term
trends in clinical trial applications in Europe were pub-
lished so far. A study similar in conception examined
the effect of EUCTD on academic drug trials in Den-
mark, based on CTA figures spanning the period from
1993 until 2006 [31]. Overall figures from the EudraCT
database, established in 2004 in order to set-up an EU-
wide clinical trial register with a unique trial identifier
for each new trial, were reported for the first time to
the general public in the EU Commission’s assessment
paper from October 2009 [8]. The data point out that
the absolute number of clinical drug trials applied for in
the whole EU increased from 3,969 in 2005 to 5,028 in
2007. Since then the absolute number of trials began to
decline; in 2009 4,491 new drug trials were initiated in
the EU (in 2010: 4,193) [11]. During this period,
approximately two-thirds of the trials were sponsored by
the pharmaceutical industry. Neither the EU Commis-
sion nor the European Medicines Agency (EMA), which
is in charge of the EudraCT database, had any compara-
tive data on file for the period prior to May 2004.
In order to gain a clearer picture of the situation, the
European Commission launched in 2008 a comprehen-
sive study on the “Impact on Clinical Research of Eur-
opean Legislation” (ICREL) [6]. ICREL was a
longitudinal, retrospective, observational and compara-
tive study to assess the impact of the EUCTD “on the
number, size, and nature of clinical trials, on workload,
resources, costs and performance” [8]. For the project,
comprehensive feedback was collected from trial spon-
sors, ethics committees and national competent authori-
ties. The impact assessment was based on mean
differences between 2003 and 2007, estimated to verify
whether a marked change occurred over time. The pro-
ject compiled a wealth of information on the EUCTD’s
outcomes [6], including feed-back from 25 national
competent authorities in the EU. The total number of
CTA per year during the observation period shifted
from 8,022 (for 2003) to 9,363 (for 2007), revealing in
accordance with the European Commission’sd a t at h e
ascendance of multinational trials in CTA rates: accord-
ing to the Commission, approximately 25% of clinical
trials in the EU are conducted in more than one coun-
try; these multinational trials account for approximately
60% of all CTA submitted in the EU [8]. Adding up all
reported trial applications, the ICREL report concluded
that the number of CTA between 2003 and 2007 did
not change significantly with an observed slight increase
of 1.5%. Respectively, a significant 10.5% increase for
CTA submitted by commercial sponsors across the EU
was reported, as well as a non-significant decrease of
25.6% in terms of CTA of non-commercial sponsors.
The report noted also that the most “important clinical
research countries experienced a certain decrease in
their research activity due to a fall in the number of
CTA sponsored by non-commercial entities”.I nc o n -
trast, “regulatory agencies with a small number of CTA
tended to slightly increase their activity over time” [6].
Nevertheless, the ICREL data regarding CTA have two
major limitations. One is the bias caused by the multiple
accounting of CTA of multinational trials: true shifts in
t h ea b s o l u t en u m b e ro ft h el a r g e l ym u l t i n a t i o n a lp h a s e
III trials, hence, impact more severely on overall figures
than shifts in the absolute number of phase I trials. The
second limitation relates to the fact that the CTA
metrics in the report were reported in an anonymous
manner, on request of some of the authorities which
provided that data. The ICREL report, therefore, does
not deliver information of how CTA rates were
impacted at the national level.
The present results reported in this paper have a dou-
ble significance. On the one hand, they provide a
detailed first-ever situation analysis for those countries
which are the heavyweights in clinical drug research in
t h eE U .O nt h eo t h e rh a n d ,t h e yr e p r e s e n tas e c o n d ,
complementary analysis of CTA data, adding evidence
to the understanding of the current situation in Europe
and providing for the first time ever trial-phase specific
m e t r i c s .A tag l a n c e ,t h ed a t ac o n f i r mI C R E L ’sf i n d i n g s
due to the fact that the source data are the same. Some
differences in the magnitude of the described trends or
in single findings are due to the differing observation
periods and the chosen methods for data analysis. But
both studies share the same main findings: (i) on the
whole, CTA rates in Europe have been struggling for
some time to show sustainable growth dynamics; (ii)
non-commercial research in Europe is much more
affected by the changed policy environment than com-
mercial research; (iii) the decrease in non-commercial
trial activities clearly affects growth rates in the leading
EU countries, that is, Germany, France and the UK; and
(iv) in some other countries, including Italy and Spain,
the overall clinical research activity developed positively.
The presented trial phase specific patterns also match
well with the first EudraCT-based data made public in
February 2011 [11]. According to the European Com-
mission, phase distribution pattern in terms of absolute
numbers of new trials were unchanged between 2007
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t i a lR & Dm o d e l ,p h a s eIt r i a l sw e r ed o m i n a n t( 3 2 . 0 %i n
average), followed by phase II (29.2%) and phase III
trials (21.5%). 17.4% of all trials in the EU are interven-
tional phase IV trials.
For a conclusive statement on the situation of clinical
drug research in Europe, two questions must be
answered. Are the observed discrepancies in growth
among the six analyzed countries meaningful? Is the
absence of growth in clinical research in Europe part of
a global trend, or a regional phenomenon?
Surely discrepancies in growth are meaningful for
patients, clinical researchers and health care systems in
each country, as clinical research is an essential compo-
nent of a high quality healthcare system [32]. Growth is
linked to improved and faster access to new, promising
therapies, the contribution to evidence-building in medi-
cine, and to investments as well as the capacity-building in
the healthcare research sector. The reported intra-Eur-
opean trends are meaningful not only from the research
perspective, but also from the public health perspective:
population-size-adjusted trial activity can be seen as a sur-
rogate indicator in terms of access to innovative medicines
and state-of-the-art medical care. In this respect, the
observed shifts among countries result in some leveling of
clinical research activities. Italy, prior to 2004 was still the
taillight in terms of numbers of initiated trials per year
and per million inhabitants (10.1 trials/year/million inha-
bitants), but has now closed the gap with its peers (Figure
2). Despite some methodological limitations and due to
the lack of quantifiable variables, the relative change of
CTA over time per country, expressed in terms of AAGR
can be considered as a valid benchmark for the present
analysis. Nevertheless, caution is required in the interpre-
tation of the presented data, as the described outcomes
are determined by complex multifactor processes.
Concerning the global situation, it was repeatedly
reported that a world-wide shift in clinical trials to so-
called emerging regions is under way [2,33]. The Eur-
opean Commission in its initial assessment report, as
well as the European Medicines Agency came to similar
conclusions, stating that in addition to North America,
particularly Asia and Latin America began to recruit
meaningful numbers of patients in international trials
used for marketing authorization applications in the EU
[8,34]. Available comparative figures from national
authorities and presentations of authority officials held
at various symposia reveal that the CTA rates in North
America and Asia over the last decade grew on average
more than 5% per annum; that is to say more than in
Europe [35]. Japan, itself facing problems with its clini-
cal research competitiveness, has reported a 4% annual
growth for the period between 2001 and 2009, doing
nearly as well as Italy. Average annual growth rates
between 5 and 10% were found for North America
(USA 7%, Canada 8%) and for several south-eastern
A s i a nc o u n t r i e s( T a i w a n6 %, Malaysia 6%, Singapore
7%). Other Asian countries, such as South Korea and
China, who adapted rather late to international trial
standards and GCP and who just began a few years ago
to get involved into the global drug development pro-
cess [36], currently experience annual growth rates of
30% and more. At a glance these comparative data
underline that the growth rates in Europe, especially the
observed decline in north-western Europe, are underpin-
ning the continent’s fall in clinical drug research.
Conclusions
In conclusion, the implementation of the EUCTD did not
result in the intended harmonization of clinical trial
requirements across the six analyzed EU member states
but in the leveling of clinical trial activities. The expected
increase of clinical research activity aimed by the EUCTD
has not occurred in Europe. In contrast, the number of
trials decreased in central and north-west Europe. Policy-
makers in the EU should take notice of the lack of growth
in a sector crucial for future biomedical competitiveness.
The process and the elements of the implementation
of the EUCTD across Europe impacted positively or
negatively on the overall outcome in respect to CTA
rates. In Italy’s case, national measures had a synergistic
effect and promoted the conduct of trials. In addition to
reduced trial approval timelines through streamlined
and more transparent processes as introduced by the
EUCTD - Italy as well as Spain benefited from this fac-
tor - the Italian measures supported non-commercial
research through adequate new funding and research
governance provisions. The additional burden imposed
by the Directive deprived the UK of its former regula-
tory simplicity - especially for Phase I trials with healthy
volunteers. This negative effect has been accentuated by
structural problems inherent to its national health care
research governance system.
Different EU member states have successfully devel-
oped best practices. In light of the reported outcomes, it
is hoped that the European national policy-makers are
exchanging their best practices gained so far. The
intended revision of the EUCTD bears the promises to
overcome the principle obstacles identified during the
last five years, to affirm Europe’s role in clinical research
and to rebuild sponsors’ and trialists’ engagement in
clinical drug research in Europe.
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